Business
Four contracts awarded worth over £3.0m
Four contracts awarded worth over £3.0m.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 1007M IXICO plc 18 January 2016 \n \n\nIXICO awarded four contracts worth a combined value of over £3.0m\nFurther cements IXICO's partnerships with leading pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease.\n \n18 January 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has recently been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over £3.0m.\n \nThe contracts are for global clinical trials of novel drugs for Alzheimer's disease which span the three major phases of drug development and are expected to run for the next two to four years, subject to the drugs successfully progressing through the clinical trials process. They will utilise IXICO's expertise in the Alzheimer's field and our proprietary TrialTracker® and Assessa® digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.\n \nThe award of these contracts builds on IXICO's expertise in brain health following a long term contract for a Phase II/III global study in neurodegenerative disease and selection as the imaging analysis partner within The European Prevention of Alzheimer's Dementia Initiative (EPAD), announced in 2015.\n \nProfessor Derek Hill, Chief Executive Officer of IXICO, commented: \"We are very pleased to have been awarded these significant projects. Not only do they validate the value our digital platforms provide, but also highlight the strength of IXICO's relationships with pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease. The revenues from these contracts augment the board's confidence in meeting market expectations.\"\n \nEnquiries:\n \n\n\n\n\nIXICO plc\n\n\n+44 20 3763 7499\n\n\n\n\nDerek Hill, CEO\n\n\n\n\n\n\n\nSusan Lowther, CFO\n\n\n\n\n\n\n\nCharles Spicer, VP Corporate Development\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Nominated Adviser and Broker)\n\n\n+44 20 7418 8900\n\n\n\n\nJames Steel / Oliver Jackson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDaniel Stewart & Company (Joint Broker)\n\n\n+44 207 776 6550\n\n\n\n\nMartin Lampshire / David Coffman\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting Li...